F S&P 500
5,111.75 +5.25 (+0.10%) F Dow Jones
38,701.00 -25.00 (-0.06%) F Nasdaq
17,694.25 +87.50 (+0.50%) E-mini Russell 2000 Index Futur
2,008.30 -6.60 (-0.33%) Petróleo
83.01 -0.35 (-0.42%) Oro
2,330.50 -11.60 (-0.50%)
Chimerix, Inc. (CMRX)
Fuera de horario:
Chimerix, Inc.
2505 Meridian Parkway
Suite 100
Durham, NC 27713
United States
919-806-1074
https://www.chimerix.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 72
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Michael T. Andriole M.B.A. | CEO, President & Director | 592.95k | N/D | 1973 |
| Dr. Allen S. Melemed M.B.A., M.D. | Chief Medical Officer | 605.29k | N/D | 1964 |
| Ms. Michelle LaSpaluto | Chief Financial Officer | N/D | N/D | 1975 |
| Mr. Thomas J. Riga | Chief Operating & Commercial Officer | N/D | N/D | 1976 |
| Mr. David Jakeman CPA | VP of Accounting & Finance | N/D | N/D | 1978 |
| Dr. Joshua E. Allen Ph.D. | Chief Technology Officer | N/D | N/D | N/D |
| Dr. Michael A. Alrutz J.D., Ph.D. | Senior VP, General Counsel & Corporate Secretary | 619.5k | N/D | 1970 |
| Dr. Roy W. Ware MBA, Ph.D. | Chief Manufacturing Technology Officer | N/D | N/D | N/D |
Descripción
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Gestión corporativa
La calificación ISS Governance QuickScore de Chimerix, Inc. a partir del 1 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 9; Junta: 7; Derechos del accionista: 8; Compensación: 8.
